COVID-19 Test Home Collection Kits Gain Popularity in Middle East and Africa
Since the U.S. Food and Drug Administration (FDA) authorized LabCorp’s Pixel COVID-19 Test Home Collection Kit, companies in the MEA direct-to-consumer laboratory testing market are taking cues from the same. Manufacturers are developing COVID-19 test home collection kits that can be used by individuals of 18 years and above without the need for a prescription. Such kits are allowing users to self-collect a nasal swab sample at home and then send that sample for testing to labs.
Companies in the MEA direct-to-consumer laboratory testing market are innovating in COVID-19 test home collection kits that enable positive or invalid results that are delivered to the user by phone call from a healthcare provider or a lab.
Lack of Regulations for Genetic DTC Testing Affects Market Growth
The MEA direct-to-consumer laboratory testing market is expected to expand at a CAGR of 18.3% during the forecast period. The cost of gene sequencing is decreasing due to advancements in next gen sequencing (NGS) and increasing availability of direct-to-consumer (DTC) laboratory testing. However, it has been found that in many cases, DTC tests are not regulated by the government healthcare organizations. Hence, healthcare companies and healthcare authorities should collaborate to implement regulations regarding DTC, and create awareness about the key differences and limitations between clinical & DTC genetic tests.
Manufacturers are increasing R&D in low cost and automated tests with automated analysis and reporting.
Companies Pursuing Opportunities in DTC Testing Due to Growth in Telehealth
The surge in the demand for DTC testing is part of a broader shift toward telehealth and eCommerce as a result of the ongoing coronavirus pandemic. Virtual care is likely to surge in the upcoming years, since weekly visits are growing at a substantial rate. Market stakeholders are setting their collaboration wheels in motion to sell new COVID-19 home sample collection kits.
Stakeholders in the MEA direct-to-consumer laboratory testing market are scaling up testing and telehealth services due to the ongoing pandemic. They have been working at break-neck speed to meet the unprecedented demand for COVID-19 home sample collection kits. Healthcare companies are expanding their marketing strategy spanning from podcosts to news channels to increase acceptance of DTC operations.
DTC Genetic Testing Enabling Access to Information on Risks of Cancer
Personalized, precision, and genomic medicines based on DNA sequencing hold potentials to offer opportunities for improving the overall public health. The MEA direct-to-consumer laboratory testing market is undergoing a significant change with DNA sequencing being applied for disease prevention such as heart diseases, cancers, and metabolic diseases.
The identification of patients’ risk profile is becoming necessary in the MEA direct-to-consumer laboratory testing market. This is explains why the market is anticipated to reach US$ 928.34 Mn by 2031. DTC genetic testing (DTCGT) is allowing access to information on their risks of suffering from a wide range of chronic diseases.
Patient-centered Patient Care Creating Revenue Opportunities for Stakeholders
Telehealth is making it possible for increasing the availability of direct-to-consumer laboratory testing. Patient-centered laboratory stewardship is acting as a key driver for the MEA direct-to-consumer laboratory testing market. There is a growing need for patient care that is respectful of and responsive to individual patient preferences, values, and needs. These trends are ensuring that patient values guide all clinical decisions.
The concept of patient centered capitalism is storming the MEA direct-to-consumer laboratory testing market. Stakeholders are prioritizing the interests of patients over those of financial and other stakeholders within both the healthcare system & its suppliers. Patient-centered laboratory stewardship is proving beneficial to improve important areas of lab testing and DTC testing such as test ordering, result retrieval, result interpretation, and financial fairness for patients and other stakeholders.
Analysts’ Viewpoint
With the COVID-19 pandemic accelerating interest in telehealth and consumer-initiated testing, companies in the MEA direct-to-consumer laboratory testing market are aiming to expand their DTC operations. DTC genetic testing aimed at guiding a patient’s diet or exercise remains largely unproven in producing better outcomes. Hence, market stakeholders should collaborate and implement laboratory stewardship programs that put in safeguards to improve patient-centered care.
Genetic counseling sessions are being conducted to explain details and options at appropriate education levels. Mobile apps are being developed to facilitate patient retrieval of results. Healthcare providers in the MEA direct-to-consumer laboratory testing market are increasing patient access to their electronic medical records. Moreover, educational materials are being written in patient’s language of choice. Enhanced communication between patients and physicians through text, phone, and electronic medical record is helping to improve patient quality of life.
Middle East & Africa Direct-to-Consumer Laboratory Testing Market: Overview
Middle East & Africa Direct-to-Consumer Laboratory Testing Market: Key Segments
Middle East & Africa Direct-to-Consumer Laboratory Testing Market: Regional Outlook
Companies Covered in Middle East & Africa Direct-to-Consumer Laboratory Testing Market Report
Middle East & Africa Direct-to-Consumer Laboratory Testing Market Snapshot
|
Attribute |
Detail |
|
Market Size Value in 2020 (Base Year) |
US$ 124.40 Mn |
|
Market Forecast Value in 2031 |
US$ 928.34 Mn |
|
Growth Rate (CAGR) |
18.3% |
|
Forecast Period |
2021–2031 |
|
Quantitative Units |
US$ Mn for Value |
|
Market Analysis |
It includes segment analysis at MEA as well as sub-region level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key industry events, etc. |
|
Competition Landscape |
Market share analysis by company (2020) |
|
Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, key financials, etc. |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Regions Covered |
MEA |
|
GCC Countries |
|
|
South Africa |
|
|
Rest of MEA |
|
|
Companies Profiled |
23andMe, Inc. |
|
Ancestry |
|
|
CircleDNA |
|
|
Eurofins Scientific |
|
|
Family Tree DNA (Gene by Gene) |
|
|
Laboratory Corporation of America Holdings |
|
|
Living DNA Ltd. |
|
|
Medichecks.com Ltd. |
|
|
MyHeritage Ltd. |
|
|
MyMedLab, Inc. |
|
|
Quest Diagnostics Incorporated |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
Middle East & Africa Direct-to-Consumer Laboratory Testing Market – Segmentation
| Test Type |
|
| Sample Type |
|
| Provider |
|
| Country/Sub-region |
|
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: MEA Direct-to-Consumer Laboratory Testing Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. MEA Direct-to-Consumer Laboratory Testing Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Industrial Events (licensing partnerships/mergers & acquisitions)
5.2. Disease Prevalence & Incidence Rate
5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. MEA Direct-to-Consumer Laboratory Testing Market Analysis and Forecast, by Sample Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Sample Type, 2017–2031
6.3.1. Blood
6.3.2. Urine
6.3.3. Saliva
6.3.4. Others
6.4. Market Attractiveness Analysis, by Sample Type
7. MEA Direct-to-Consumer Laboratory Testing Market Analysis and Forecast, by Test Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Test Type, 2017–2031
7.3.1. Genetic Testing
7.3.1.1. Nutrigenetics Test
7.3.1.1.1. Weight Control
7.3.1.1.2. Lactose Intolerance
7.3.1.1.3. Others
7.3.1.2. Celiac Disease Test
7.3.1.3. Sports & Physical Activity Testing
7.3.1.4. Men's Health Tests
7.3.1.5. Women's Health Tests
7.3.1.6. Pregnancy & Prenatal Screening Test
7.3.1.7. General Health Testing
7.3.1.8. Others
7.3.2. Disease Risk Assessment Testing
7.3.2.1. Sexual Health Tests
7.3.2.1.1. HIV
7.3.2.1.2. Chlamydia
7.3.2.1.3. Others
7.3.2.2. Cancer Predisposition Tests
7.3.2.3. Others
7.3.3. CBC
7.3.4. Chronic Disease Testing
7.3.4.1. Diabetes Testing
7.3.4.2. Hypertension
7.3.4.3. Others
7.3.5. COVID-19 Testing
7.3.6. TSH Testing
7.3.7. Others
7.4. Market Attractiveness Analysis, by Test Type
8. MEA Direct-to-Consumer Laboratory Testing Market Analysis and Forecast, by Provider
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Provider, 2017–2031
8.3.1. Hospitals
8.3.2. Clinics
8.3.3. Specialty Labs
8.3.4. Diagnostic Centers
8.4. Market Attractiveness Analysis, by Provider
9. GCC Countries Direct-to-Consumer Laboratory Testing Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Sample Type, 2017–2031
9.2.1. Blood
9.2.2. Urine
9.2.3. Saliva
9.2.4. Others
9.3. Market Value Forecast, by Test Type, 2017–2031
9.3.1. Genetic Testing
9.3.1.1. Nutrigenetics Test
9.3.1.1.1. Weight Control
9.3.1.1.2. Lactose Intolerance
9.3.1.1.3. Others
9.3.1.2. Celiac Disease Test
9.3.1.3. Sports & Physical Activity Testing
9.3.1.4. Men's Health Tests
9.3.1.5. Women's Health Tests
9.3.1.6. Pregnancy & Prenatal Screening Test
9.3.1.7. General Health Testing
9.3.1.8. Others
9.3.2. Disease Risk Assessment Testing
9.3.2.1. Sexual Health Tests
9.3.2.1.1. HIV
9.3.2.1.2. Chlamydia
9.3.2.1.3. Others
9.3.2.2. Cancer Predisposition Tests
9.3.2.3. Others
9.3.3. CBC
9.3.4. Chronic Disease Testing
9.3.4.1. Diabetes Testing
9.3.4.2. Hypertension
9.3.4.3. Others
9.3.5. COVID-19 Testing
9.3.6. TSH Testing
9.3.7. Others
9.4. Market Value Forecast, by Provider, 2017–2031
9.4.1. Hospitals
9.4.2. Clinics
9.4.3. Specialty Labs
9.4.4. Diagnostic Centers
10. South Africa Direct-to-Consumer Laboratory Testing Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Sample Type, 2017–2031
10.2.1. Blood
10.2.2. Urine
10.2.3. Saliva
10.2.4. Others
10.3. Market Value Forecast, by Test Type, 2017–2031
10.3.1. Genetic Testing
10.3.1.1. Nutrigenetics Test
10.3.1.1.1. Weight Control
10.3.1.1.2. Lactose Intolerance
10.3.1.1.3. Others
10.3.1.2. Celiac Disease Test
10.3.1.3. Sports & Physical Activity Testing
10.3.1.4. Men's Health Tests
10.3.1.5. Women's Health Tests
10.3.1.6. Pregnancy & Prenatal Screening Test
10.3.1.7. General Health Testing
10.3.1.8. Others
10.3.2. Disease Risk Assessment Testing
10.3.2.1. Sexual Health Tests
10.3.2.1.1. HIV
10.3.2.1.2. Chlamydia
10.3.2.1.3. Others
10.3.2.2. Cancer Predisposition Tests
10.3.2.3. Others
10.3.3. CBC
10.3.4. Chronic Disease Testing
10.3.4.1. Diabetes Testing
10.3.4.2. Hypertension
10.3.4.3. Others
10.3.5. COVID-110 Testing
10.3.6. TSH Testing
10.3.7. Others
10.4. Market Value Forecast, by Provider, 2017–2031
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Specialty Labs
10.4.4. Diagnostic Centers
11. Rest of MEA Direct-to-Consumer Laboratory Testing Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Sample Type, 2017–2031
11.2.1. Blood
11.2.2. Urine
11.2.3. Saliva
11.2.4. Others
11.3. Market Value Forecast, by Test Type, 2017–2031
11.3.1. Genetic Testing
11.3.1.1. Nutrigenetics Test
11.3.1.1.1. Weight Control
11.3.1.1.2. Lactose Intolerance
11.3.1.1.3. Others
11.3.1.2. Celiac Disease Test
11.3.1.3. Sports & Physical Activity Testing
11.3.1.4. Men's Health Tests
11.3.1.5. Women's Health Tests
11.3.1.6. Pregnancy & Prenatal Screening Test
11.3.1.7. General Health Testing
11.3.1.8. Others
11.3.2. Disease Risk Assessment Testing
11.3.2.1. Sexual Health Tests
11.3.2.1.1. HIV
11.3.2.1.2. Chlamydia
11.3.2.1.3. Others
11.3.2.2. Cancer Predisposition Tests
11.3.2.3. Others
11.3.3. CBC
11.3.4. Chronic Disease Testing
11.3.4.1. Diabetes Testing
11.3.4.2. Hypertension
11.3.4.3. Others
11.3.5. COVID-19 Testing
11.3.6. TSH Testing
11.3.7. Others
11.4. Market Value Forecast, by Provider, 2017–2031
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Specialty Labs
11.4.4. Diagnostic Centers
12. Competition Landscape
12.1. Market Player - Competition Matrix (by tier and size of companies)
12.2. Company Profiles
12.2.1. 23andMe, Inc.
12.2.1.1. Company Description
12.2.1.2. Business Overview
12.2.1.3. Strategic Overview
12.2.1.4. SWOT Analysis
12.2.2. Ancestry
12.2.2.1. Company Description
12.2.2.2. Business Overview
12.2.2.3. SWOT Analysis
12.2.3. CircleDNA
12.2.3.1. Company Description
12.2.3.2. Business Overview
12.2.3.3. SWOT Analysis
12.2.4. Eurofins Scientific
12.2.4.1. Company Description
12.2.4.2. Business Overview
12.2.4.3. Financial Overview
12.2.4.4. SWOT Analysis
12.2.5. Family Tree DNA (Gene by Gene)
12.2.5.1. Company Description
12.2.5.2. Business Overview
12.2.5.3. SWOT Analysis
12.2.6. Laboratory Corporation of America Holdings
12.2.6.1. Company Description
12.2.6.2. Business Overview
12.2.6.3. Financial Overview
12.2.6.4. Strategic Overview
12.2.6.5. SWOT Analysis
12.2.7. Living DNA Ltd.
12.2.7.1. Company Description
12.2.7.2. Business Overview
12.2.7.3. SWOT Analysis
12.2.8. Medichecks.com Ltd.
12.2.8.1. Company Description
12.2.8.2. Business Overview
12.2.8.3. SWOT Analysis
12.2.9. MyHeritage Ltd.
12.2.9.1. Company Description
12.2.9.2. Business Overview
12.2.9.3. SWOT Analysis
12.2.10. MyMedLab, Inc.
12.2.10.1. Company Description
12.2.10.2. Business Overview
12.2.10.3. SWOT Analysis
12.2.11. Quest Diagnostics Incorporated
12.2.11.1. Company Description
12.2.11.2. Business Overview
12.2.11.3. Financial Overview
12.2.11.4. Strategic Overview
12.2.11.5. SWOT Analysis
List of Tables
Table 01: MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Sample Type, 2017–2031
Table 02: MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 03: MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Genetic Testing, 2017–2031
Table 04: MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Nutrigenetics Test, 2017–2031
Table 05: MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Disease Risk Assessment Testing, 2017–2031
Table 06: MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Sexual Health Tests, 2017–2031
Table 07: MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Chronic Disease Testing, 2017–2031
Table 08: MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Provider, 2017–2031
Table 09: GCC Countries Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Sample Type, 2017–2031
Table 10: GCC Countries Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 11: GCC Countries Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Genetic Testing, 2017–2031
Table 12: GCC Countries Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Nutrigenetics Test, 2017–2031
Table 13: GCC Countries Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Disease Risk Assessment Testing, 2017–2031
Table 14: GCC Countries Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Sexual Health Tests, 2017–2031
Table 15: GCC Countries Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Chronic Disease Testing, 2017–2031
Table 16: GCC Countries Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Provider, 2017–2031
Table 17: SOUTH AFRICA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Sample Type, 2017–2031
Table 18: SOUTH AFRICA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 19: SOUTH AFRICA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Genetic Testing, 2017–2031
Table 20: SOUTH AFRICA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Nutrigenetics Test, 2017–2031
Table 21: SOUTH AFRICA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Disease Risk Assessment Testing, 2017–2031
Table 22: SOUTH AFRICA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Sexual Health Tests, 2017–2031
Table 23: SOUTH AFRICA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Chronic Disease Testing, 2017–2031
Table 24: SOUTH AFRICA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Provider, 2017–2031
Table 25: Rest of MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Sample Type, 2017–2031
Table 26: Rest of MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 27: Rest of MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Genetic Testing, 2017–2031
Table 28: Rest of MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Nutrigenetics Test, 2017–2031
Table 29: Rest of MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Disease Risk Assessment Testing, 2017–2031
Table 30: Rest of MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Sexual Health Tests, 2017–2031
Table 31: Rest of MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Chronic Disease Testing, 2017–2031
Table 32: Rest of MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, by Provider, 2017–2031
List of Figures
Figure 01: MEA Direct-to-Consumer Laboratory Testing Market Value Share Analysis, by Sample Type, 2020 and 2031
Figure 02: MEA Direct-to-Consumer Laboratory Testing Market Attractiveness Analysis, by Sample Type, 2021–2031
Figure 03: MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn), by Blood, 2017–2031
Figure 04: MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn), by Urine, 2017–2031
Figure 05: MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn), by Urine, 2017–2031
Figure 06: MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn), by Others, 2017–2031
Figure 07: MEA Direct-to-Consumer Laboratory Testing Market Value Share Analysis, by Test Type, 2020 and 2031
Figure 08: MEA Direct-to-Consumer Laboratory Testing Market Attractiveness Analysis, by Test Type, 2021–2031
Figure 09: MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn), by Genetic Testing, 2017–2031
Figure 10: MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn), by Disease Risk Assessment Testing, 2017–2031
Figure 11: MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn), by CBC, 2017–2031
Figure 12: MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn), by Chronic Disease Testing, 2017–2031
Figure 13: MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn), by COVID-19 Testing, 2017–2031
Figure 14: MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn), by TSH Testing, 2017–2031
Figure 15: MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn), by Others, 2017–2031
Figure 16: MEA Direct-to-Consumer Laboratory Testing Market Value Share Analysis, by Provider, 2020 and 2031
Figure 17: MEA Direct-to-Consumer Laboratory Testing Market Attractiveness Analysis, by Provider, 2021–2031
Figure 18: MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn), by Hospitals, 2017–2031
Figure 19: MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn), by Clinics, 2017–2031
Figure 20: MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn), by Specialty Labs, 2017–2031
Figure 21: MEA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn), by Diagnostic Centers, 2017–2031
Figure 22: GCC Countries Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, 2017–2031
Figure 23: GCC Countries Direct-to-Consumer Laboratory Testing Market Value Share Analysis, by Sample Type, 2020 and 2031
Figure 24: GCC Countries Direct-to-Consumer Laboratory Testing Market Attractiveness Analysis, by Sample Type, 2021–2031
Figure 25: GCC Countries Direct-to-Consumer Laboratory Testing Market Value Share Analysis, by Test Type, 2020 and 2031
Figure 26: GCC Countries Direct-to-Consumer Laboratory Testing Market Attractiveness Analysis, by Test Type, 2021–2031
Figure 27: GCC Countries Direct-to-Consumer Laboratory Testing Market Value Share Analysis, by Provider, 2020 and 2031
Figure 28: GCC Countries Direct-to-Consumer Laboratory Testing Market Attractiveness Analysis, by Provider, 2021–2031
Figure 29: SOUTH AFRICA Direct-to-Consumer Laboratory Testing Market Value (US$ Mn) Forecast, 2017–2031
Figure 30: SOUTH AFRICA Direct-to-Consumer Laboratory Testing Market Value Share Analysis, by Sample Type, 2020 and 2031
Figure 31: SOUTH AFRICA Direct-to-Consumer Laboratory Testing Market Attractiveness Analysis, by Sample Type, 2021–2031
Figure 32: SOUTH AFRICA Direct-to-Consumer Laboratory Testing Market Value Share Analysis, by Test Type, 2020 and 2031
Figure 33: SOUTH AFRICA Direct-to-Consumer Laboratory Testing Market Attractiveness Analysis, by Test Type, 2021–2031
Figure 34: SOUTH AFRICA Direct-to-Consumer Laboratory Testing Market Value Share Analysis, by Provider, 2020 and 2031
Figure 35: SOUTH AFRICA Direct-to-Consumer Laboratory Testing Market Attractiveness Analysis, by Provider, 2021–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Middle East Africa Direct-to-Consumer Laboratory Testing Market Outlook, 2021-2031
